Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8856944 | 0.84 | FABP4 (0.48) | KDM4EHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL5682959 | 0.83 | KDM4E (0.47) | KDM4EHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL13715488 | 0.82 | KDM4E (0.62) | KDM4EHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL7596917 | 0.81 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL5682857 | 0.80 | KDM4E (0.45) | KDM4EHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL8846631 | 0.79 | TSHR (0.45) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5686136 | 0.78 | HSD17B10 (0.43) | KDM4EHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL8887655 | 0.77 | KDM4E (0.42) | KDM4EHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL7593462 | 0.77 | KMT2A (0.50) | KDM4EHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL3256019 | 0.76 | TSHR (0.47) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3837008-B1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2025-09-24 | — | — | EP | disclosed |
| US-20250064761-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2025-02-27 | — | — | US | disclosed |
| EP-3836912-B1 | COMBINATIONS OF SUBSTITUTED BENZAMIDES AND 5-ASA AGENTS | PHARMACYL AB (SE) | 2024-05-01 | — | — | EP | disclosed |
| US-11896564-B2 | Medical treatment for pathologic inflammation | PHARMACYL AB (SE) | 2024-02-13 | — | — | US | disclosed |
| US-11717500-B2 | Treatment of spondyloarthritis | PHARMACYL AB (SE) | 2023-08-08 | — | — | US | disclosed |
| US-20220087959-A1 | A NEW MEDICAL TREATMENT FOR PATHOLOGIC INFLAMMATION | PHARMACYL AB (SE) | 2022-03-24 | — | — | US | disclosed |
| US-20210299071-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2021-09-30 | — | — | US | disclosed |
| US-20210236441-A1 | TREATMENT OF SPONDYLOARTHRITIS | PHARMACYL AB (SE) | 2021-08-05 | — | — | US | disclosed |
| EP-3836912-A1 | A NEW MEDICAL TREATMENT FOR PATHOLOGIC INFLAMMATION | Pharmacyl AB (SE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3837008-A2 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | Pharmacyl AB (SE) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020035555-A2 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035554-A1 | A NEW MEDICAL TREATMENT FOR PATHOLOGIC INFLAMMATION | PHARMACYL AB (SE) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11896564-B2 | Medical treatment for pathologic inflammation | KIT, IL5, IL6 | KDM4E 2089/4885HSD17B10 1316/4885ALDH1A1 71/4885 |
| US-20250064761-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | BRD4, SI, BRD7 | KDM4E 1423/4885HSD17B10 2271/4885ALDH1A1 719/4885 |
| US-11717500-B2 | Treatment of spondyloarthritis | SPAST, IL17A, SLC10A2 | KDM4E 4389/4885HSD17B10 1150/4885ALDH1A1 1318/4885 |
| US-20210236441-A1 | TREATMENT OF SPONDYLOARTHRITIS | SPAST, IL17A, SLC10A2 | KDM4E 4389/4885HSD17B10 1150/4885ALDH1A1 1318/4885 |
| US-20220087959-A1 | A NEW MEDICAL TREATMENT FOR PATHOLOGIC INFLAMMATION | KIT, IL5, IL1B | KDM4E 2094/4885HSD17B10 1208/4885ALDH1A1 73/4885 |
| US-20210299071-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | BRD4, SI, BRD7 | KDM4E 1423/4885HSD17B10 2271/4885ALDH1A1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.